Torrent Pharma yesterday said that it is introducing MSD and Ridgeback’s Molnupiravir under the brand name Molnutor in India. Earlier this year, MSD inked a non-exclusive voluntary licensing pact with Torrent Pharma, granting rights to the latter for manufacturing, distribution and marketing of Molnupiravir in more than 100 low-and middle-income markets, including India, for treatment of COVID-19, the company notified via a statement.
The Drugs Controller General of India (DCGI), based on the review of clinical data of Molnupiravir has approved the drug for the treatment of COVID-19 in adults for restricted emergency use in India, the statement added.